Day: April 8, 2020

 AttachmentEN_NCX 4251 FDA MEETING_20200408_F

 Pièce jointeFR _NCX 4251 FDA_MEETING_20200408_F

Paris, Amsterdam, April 8, 2020Press releaseInformation related to the compensation of Unibail-Rodamco-Westfield senior executivesDue to the COVID-19 pandemic, Unibail-Rodamco-Westfield (URW or “the Group”) has implemented partial activity measures in various countries to protect its employees, preserve employment where possible and to allow a swift return to full capacity as soon as health and safety conditions permit.As a sign of solidarity with all employees, and with the full support of the Supervisory Board of URW, the Group CEO, Christophe Cuvillier, the Group CFO, Jaap Tonckens, and all members of the Group’s Senior Management Team have taken the initiative to reduce their remuneration by -25% for the period during which the partial activity measures will be in place. In recognition of this effort, the members of URW’s Supervisory...

Delta Drone anticipe l’après-crise sanitaire et sécurisele financement de sa croissanceSignature d’un contrat d’ORNAN assorties de BSA de 10 M€ avec Yorkville Advisors, sous réserve de l’approbation de l’AGE du 24 avril 2020Dardilly, 8 avril 2020Préambule : Risques liés à l’émission et impacts de l’opération en termes de gestion du risque de liquidité et d’horizon de financementCompte tenu d’une situation de trésorerie de 2,5 M€ à fin mars 2020, la mise en place du nouveau financement par voie d’émission de bons d’émission lesquels donneraient lieu, sur exercice, à l’émission d’ORNAN assorties de BSA, permettrait de passer à une capacité minimale de 12,5 M€ de trésorerie, ce qui correspond à plusieurs années de couverture des besoins de financement.Cette analyse tient compte de la situation actuelle et de l’exécution du plan 2020/2021,...

WISeKey International Holding Ltd Announces the Agenda of its 2020 Annual General Meeting Zug, Switzerland, April 8, 2020 – WISeKey International Holding Ltd. (“WISeKey” or “Company”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity and IoT company, announced today that the Board of Directors has recommended certain proposals for shareholder approval at the 2020 Annual General Meeting of Shareholders (“AGM“).The AGM will be held in accordance with the Swiss Federal Council Ordinance on Measures to Combat the Coronavirus of March 13, 2020. Thus, due to the extraordinary situation in connection with the COVID-19 (coronavirus) pandemic, the AGM will not  take place in the usual format and  shareholders will not be able to attend the AGM in person. The AGM will take place at the offices of the law firm Homburger AG, Prime Tower,...

Schibsted’s employee share saving plan (ESSP) continues in 2020 with saving in the Schibsted B-share.Attached to this release is a list of primary insiders that have subscribed to the share saving plan for 2020. The subscribed amount disclosed is the total amount in NOK for 2020. Primary insiders can only change their savings amount once a year. The purchase price and the number of shares will be reported when allocations are made.For more information on the employee share saving plan please refer to the disclosure published 09 April 2014.Oslo, 08 April 2020SCHIBSTED ASAThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentESSP 2020 Primary Insiders Participation

Robust cash position at December 31, 2019 of CHF 31.5 million providing runway through 2021Awarded Eurostars / Innosuisse grant of €4.85 million supporting mGlu7 NAM PTSD programAdditional funding of $1.6 million in 2019 from Indivior to support GABAB PAM addiction programDipraglurant pivotal registration study in PD-LID ready to start dosing patients subject to lifting of restrictions in US associated with the global Covid-19 crisisGeneva, Switzerland, April 8, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its full-year audited results for the year ended December 31, 2019 and provided a corporate update.“We made significant progress in 2019 in advancing our pipeline of innovative in-house discovered...

Pratteln, Switzerland, April 8, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that it has entered into an equity-linked financing arrangement with IRIS (France) in the initial gross amount of up to CHF 12 million over 12 months, with the option to extend by another CHF 12 million over another 12 months. IRIS will receive Santhera shares to be created from the Company’s authorized capital and is expected to sell these shares on the market or in block trades. It remains at the sole discretion of Santhera to suspend or terminate the staggered financing.

Pratteln, Schweiz, 8. April 2020 – Santhera Pharmaceuticals (SIX: SANN) gibt den Abschluss einer aktiengebundenen Finanzierungsvereinbarung mit IRIS (Frankreich) mit anfänglichem Bruttobetrag von bis zu CHF 12 Millionen über 12 Monate und mit der Option auf eine Erhöhung um zusätzliche CHF 12 Millionen über weitere 12 Monate bekannt. IRIS wird aus dem genehmigten Kapital des Unternehmens zu schaffende Santhera-Aktien erhalten und diese erwartungsgemäss am Kapitalmarkt oder im Blockhandel verkaufen. Es liegt im alleinigen Ermessen von Santhera, die gestaffelte Finanzierung auszusetzen oder zu beenden.Die aktiengebundene Finanzierung wurde eingerichtet, um zusätzliche Liquidität zur Unterstützung der laufenden Zulassungs- und Entwicklungsprogramme des Unternehmens in einer Gesamthöhe von bis zu CHF 24 Millionen über einen Zeitraum von bis...

Press ReleaseAntwerp (Berchem), 8 April 2020, 07h00 CETThe shareholders are hereby invited to attend the annual and extraordinary shareholders’ meeting of the Company which shall take place at registered office of the Company, at Uitbreidingstraat 72, 2600 Antwerp, Belgium, on Friday 8 May 2020 at 10:00 am, with following agenda and proposed resolutions:Information note:The board of directors closely monitors the evolution of the Covid-19 pandemic and the sanitary regulations issued by the Belgian authorities in this regard and continues to evaluate the impact thereof on the organisation of the shareholders’ meetings.The board of directors has at this stage decided not to postpone the shareholders’ meetings. The Company will however take appropriate measures to ensure that the shareholders’ meetings take place in compliance with the sanitary...